Postoperative adjuvant transarterial chemoembolization (pa-TACE) significantly improves survival in hepatocellular carcinoma (HCC) patients after liver resection.

• Patients receiving pa-TACE had 30% lower recurrence risk (HR=0.70, p=0.04) and 35% better survival rates (HR=0.65, p=0.04) compared to controls.
• The benefits are pronounced in microvascular invasion-positive patients, with recurrence-free survival improved by 69% (HR=0.31, p<0.001) and overall survival improved by 53% (HR=0.47, p=0.002).

Consider adding pa-TACE for patients post-hepatectomy, especially those at high risk for recurrence.